MARKET

STRO

STRO

Sutro Biopharma
NASDAQ
30.20
+1.40
+4.86%
After Hours: 29.75 -0.45 -1.49% 18:30 06/15 EDT
OPEN
29.29
PREV CLOSE
28.80
HIGH
30.72
LOW
28.80
VOLUME
188.65K
TURNOVER
--
52 WEEK HIGH
43.85
52 WEEK LOW
6.74
MARKET CAP
500.43M
P/E (TTM)
-1.8466
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at STRO last week (0608-0612)?
Weekly Report · 14h ago
Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities
Dow Jones · 4d ago
Sutro Biopharma Coverage Assumed by Truist Securities at Buy
Dow Jones · 4d ago
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50
Benzinga · 4d ago
Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Sutro Biopharma (STRO) and Ardent Health Partners, Inc. (ARDT)
TipRanks · 4d ago
Sutro Biopharma assumed with a Buy at Truist
TipRanks · 4d ago
SUTRO BIOPHARMA INC <STRO.O>: TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $50
Reuters · 4d ago
U.S. RESEARCH ROUNDUP-Arthur J. Gallagher & Co, Datadog, Oracle
Reuters · 4d ago
More
About STRO
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.

Webull offers Sutro Biopharma Inc stock information, including NASDAQ: STRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STRO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading STRO stock methods without spending real money on the virtual paper trading platform.